Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Million
Sep 12, 2022•almost 3 years ago
Description
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a non-dilutive royalty financing agreement with OrbiMed for up to $250 million. Proceeds from the agreement will strengthen Adaptive’s balance sheet, which stood at over $450 million in cash and marketable securities at the end of the second quarter of 2022, and provide the Company with additional capital to support its growth trajectory and path to profitability.
FundzWatch™ Score
67
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood